Veterinary PV
A pharmacovigilance system built for human medicines does not become a veterinary one just by changing the species field

About
Regulation (EU) 2019/6 shares its foundations with human GVP, but diverges on the details that actually matter: species-specific reactions, safety for non-target animals and the people handling the product, environmental impact, and for food-producing animals, Maximum Residue Limits.
A PV system adapted from human pharmacovigilance is structurally built to miss these points, and the gap shows up first in the PSMF-v and in EVVet reporting. We build the VGVP structure the regulation actually requires: PSMF-v documentation, EVVet reporting, and benefit-risk assessments defined around animal health from the start.













